These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [A case of superior vena cava syndrome treated with combination radiation and CRE (CBDCA and VP-16) therapy].
    Author: Kato M, Akimoto S, Akimoto K, Komatsu T, Nakaoka Y, Kinoshita M, Minami K, Sekikawa S, Kasahara T, Shimizu T, Kizu O, Maeda T.
    Journal: Gan To Kagaku Ryoho; 1996 Jan; 23(1):119-22. PubMed ID: 8546462.
    Abstract:
    Carboplatin and etoposide were reported to be excellent radiation sensitizers. We encountered a patient with SVC syndrome due to lung cancer who was successfully treated by combination carboplatin, etoposide and hyperfractionation radiotherapy. A 72-year-old man was admitted to our hospital because of remarkable face edema. Computed tomography revealed a huge lung tumor and compressed SVC due to tumor growth. Acute tumor regression was essential for this case. We performed combination chemotherapy and radiation. The regime consisted of CBDCA 300 mg (day 1 1 hr drip infusion) and etoposide 50 mg/day for 21 days by oral administration. Two daily fractionations of 1.4 Gy were delivered 5 days-a-week, with a 4 h interval between fractions (total dose 49.8 Gy). Complete response of huge tumor was attained in this case. The major side effect associated with the therapy was myelosuppression. The patient's quality of life has been remarkably improved with this therapy.
    [Abstract] [Full Text] [Related] [New Search]